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Abstract
Antibody mediated rejection remains an important barrier to optimal long-term out-
comes after kidney transplantation. Donor specific antibody, while not the formidable 
barrier to transplantation it once was, remains a major risk factor for antibody mediated 
rejection and its consequences of premature graft failure. Recent advances in understand-
ing of the cellular and molecular mechanisms of antibody production and antibody-
mediated injury have led to refinements in diagnostic techniques, and have paved the 
way for the development of novel therapies to treat rejection and prolong allograft func-
tion. The purpose of this chapter is to review the current level at which we understand 
the pathophysiology of antibody mediated rejection, describe the current diagnostic cri-
teria for antibody mediated rejection, and discuss available and emerging treatments as 
well as their outcomes.
Keywords: kidney transplantation, donor specific antibody, antibody mediated 
rejection
1. Introduction
The first successful kidney transplant was performed between identical twins by Joseph 
E. Murray and his colleagues at the Peter Bent Brigham Hospital in 1954 [1]. Since then, the 
field of kidney transplantation has progressed immensely owing to greater understanding of 
the immune mechanisms underlying allograft rejection at a cellular and molecular level and 
development of increasingly potent immunosuppressive drug therapies [2]. Today, kidney 
transplantation is considered the treatment of choice for patients with end stage renal disease 
(ESRD) since it is associated with lower mortality and cardiovascular morbidity while offering 
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improved quality of life [3]. However, allograft rejection remains a major impediment to the 
longevity of renal allografts. Recognition of donor antigens as “non-self” by the host immune 
system elicits humoral and cell mediated immune responses that if left unchecked result in 
the destruction of the allograft (Figure 1).
2. Human leukocyte antigen (HLA) system and allograft rejection
Human leukocyte antigens (HLA) play a vital role in host defense against foreign patho-
gens and in immune surveillance of tumors. These antigens are encoded by the major his-
tocompatibility complex (MHC) which is a family of genes that encompasses a 3.6 million 
base pair genomic region, 6p21, on the short arm of chromosome 6 [5]. The MHC complex 
is divided into three regions representing three classes of genes—classes I, II, and III. The 
HLA genes that are involved in the immune response belong to classes, I and II [6]. Class 
I antigens are expressed on all nucleated cells whereas class II antigens are expressed only 
on professional antigen presenting cells (APCs)—dendritic cells, B-cells, and macrophages 
[7]. In the setting of infection, pathogen derived foreign antigens are presented to T-cells as 
peptides on the surface of major histocompatibility complex (MHC) molecules expressed 
on the surface of APCs. The ensuing signaling cascade results in the activation, prolifera-
tion, and differentiation of naïve T lymphocytes into subtypes with distinct cytokine pro-
files. Type 1 helper T (Th1) cells drive the cellular immune response mediated by CD8+ 
cytotoxic T lymphocytes, and type 2 helper T (Th2) cells drive B-cell mediated humoral 
immune response [2].
The heterogeneity of human MHC molecules enables the immune system to protect us 
from a variety of foreign pathogens. However, in the context of transplantation between 
genetically distinct individuals, these MHC polymorphisms elicit immune responses that 
can result in rejection of the allograft [7]. Two pathophysiologically distinct flavors of renal 
allograft rejection are recognized—cell mediated, and antibody mediated rejection. Both 
these types of rejection can manifest as acute or chronic clinicopathologic variants. Acute cell 
mediated rejection is characterized by infiltration of the allograft by effector T cells result-
ing in the typical features such as tubulitis, interstitial inflammation and in more advanced 
cases, endothelial arteritis [2, 8].
Figure 1. In AMR, DSAs bind to human leukocyte antigens on graft vascular endothelium. This is followed by activation 
of complement, membrane attack complex-mediated cellular injury and infiltration of mononuclear cells. Reproduced 
with permission from Montgomery et al. [4].
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3. Clinical relevance of antibody mediated rejection
AMR is estimated to occur in 3–10% of transplant recipients and it represents 20–30% of epi-
sodes of acute rejection [7]. Although less common than cell mediated rejection, AMR is gen-
erally recognized to have a worse prognosis and requires different forms of therapy [9]. In the 
1960s anti-HLA antibodies were recognized as a cause for allograft rejection following reports 
of hyperacute antibody mediated rejection in patients with antibodies reactive to donor lym-
phocytes [10, 11]. Patel and Terasaki’s landmark study documented immediate graft failure in 
24 of 30 (80%) of the patients with circulating donor reactive antibodies identified by a posi-
tive cytotoxicity crossmatch [12]. This led to the universal practice of antibody screening by 
complement dependent cytotoxicity (CDC) crossmatch prior to renal transplantation and the 
avoidance of transplantation in patients with a positive crossmatch. Therefore, until the mid-
1980s, acute cellular rejection, as opposed to antibody mediated rejection (AMR), was con-
sidered the major barrier to successful [13]. The advent of calcineurin inhibitors (CNIs) in the 
1980s led to a significant decline in incidence of acute rejection and a consequent improvement 
in short term graft survival rates [14]. Today, cellular rejection seldom causes graft loss [15]. 
However, contemporary data suggests that these gains have not led to sustained improve-
ment in long-term graft survival [16]. Reasons for the lack of improvement in long-term graft 
survival have been a topic of much debate and most late graft losses were attributed to either 
chronic allograft nephropathy (CAN) or death with a functioning graft [17]. Although, the 
multifactorial nature of late renal allograft loss makes therapeutic intervention challenging 
[18] prevention and treatment of AMR holds the key to optimizing long term graft survival.
Exposure to non-self HLA by way of pregnancy, blood transfusion or transplantation may lead 
to the development of circulating anti-HLA antibodies. ESRD patients who are sensitized to 
HLA by prior exposure have a prolonged wait-time for transplantation and reduced transplant 
rates. Removal of pre-formed circulating donor specific antibodies (DSA) by various desensiti-
zation techniques allows transplantation of many of these biologically disadvantaged patients 
[19–21] However, such HLA incompatible kidney transplants recipients are at increased risk 
for developing AMR. A high percentage of episodes of AMR are difficult to treat and may cause 
immediate graft loss or delayed transplant glomerulopathy [22]. Therefore, AMR remains a 
significant impediment to the success of transplantation in this subset of patients.
4. Diagnosis of antibody mediated rejection
The Banff classification schema has been used internationally for scoring and classifying kid-
ney transplant pathology findings since its first iteration was published in 1993. However, 
earlier versions dealt with AMR in an imprecise manner. The development of more sophisti-
cated methods of detection of DSAs by means of solid-phase assays together with the sensi-
tivity and specificity of C4d staining in peritubular capillaries in identifying AMR paved the 
way for rigorous morphological classification of AMR [23]. The cornerstones for the diagnosis 
for AMR are (1) Histologic evidence of acute tissue injury; (2) Evidence of current/recent anti-
body interaction with vascular endothelium; (3) Serologic evidence of DSAs. The updated 
2015 Banff classification system recognizes acute active AMR and chronic active AMR and 
outlines detailed criteria for the diagnosis of each (Table 1) [24].
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Acute/active AbMR All three features must be present for diagnosis. Biopsies showing histological features plus 
evidence of current/recent antibody interaction with vascular endothelium or DSA, but not 
both, may be designated as suspicious for acute/active ABMR. Lesions may be clinically acute 
or smoldering or may be subclinical; it should be noted if the lesion is C4d-positive or C4d-
negative, based on the following criteria:
1. Histologic evidence of acute tissue injury, including one or more of the following:
• Microvascular inflammation (ga > 0 in the absence of recurrent or de novo glomerulonephri-
tis, and/or ptcb > 0)
• Intimal or transmural arteritis (vc > 0)
• Acute thrombotic microangiopathy in the absence of any other cause
• Acute tubular injury in the absence of any other apparent cause
2. Evidence of current/recent antibody interaction with vascular endothelium, including at 
least one of the following:
• Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections or 
C4d >0 by IHC on paraffin sections)
• At least moderate microvascular inflammation ([g + ptc] ≥2), although in the presence of 
acute T-cell mediated rejection (TCMR), borderline infiltrate, or infection; ptc ≥2 alone is 
not sufficient, and g must be ≥1
• Increased expression of gene transcripts in the biopsy tissue indicative of endothelial 
injury, if thoroughly validated
3. Serologic evidence of DSAs (HLA or other antigens)
Biopsies suspicious for AMR on the basis of meeting criteria 1 and 2 should prompt expedited 
DSA testing
Chronic active ABMR All three features must be present for diagnosis. As with acute/active ABMR, biopsies 
showing histological features plus evidence of current/recent antibody interaction with 
vascular endothelium or DSA, but not both, may be designated as suspicious, and it should be 
noted if the lesion is C4d-positive or C4d-negative, based on the criteria listed:
1. Histologic evidence of chronic tissue injury, including one or more of the following:
• TG (cgd > 0), if no evidence of chronic thrombotic microangiopathy; includes changes 
evident by EM only
• Severe peritubular capillary basement membrane multilayering (requires EM)c
• Arterial intimal fibrosis of new onset, excluding other causes; leukocytes within the scle-
rotic intima favor chronic ABMR if there is no prior history of biopsy-proven TCMR with 
arterial involvement but are not required
2. Evidence of current/recent antibody interaction with vascular endothelium, including at 
least one of the following:
• Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or 
C4d >0 by IHC on paraffin sections)
• At least moderate microvascular inflammation ([g + ptc] ≥2), although in the presence of 
acute TCMR, borderline infiltrate, or infection, ptc ≥2 alone is not sufficient and g must be ≥1
3. Serologic evidence of DSAs (HLA or other antigens):
• Biopsies suspicious for AMR on the basis of meeting criteria 1 and 2 should prompt expe-
dited DSA testing
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Glomerular and/or peritubular capillary infiltration with polymorphonuclear leukocytes and/
or macrophages represents microvascular inflammation and is the classic histologic feature 
of acute tissue injury in acute AMR (Figure 2). However, intimal or transmural arteritis, acute 
TMA and ATN can also denote acute AMR (Figure 3). Splitting or double contouring of the 
GBM (transplant glomerulopathy) as well as severe multi-lamination of peritubular capillary 
basement membrane are histologic features of chronic AMR. Detection of inert complement 
split product, C4d in peritubular capillaries by IF or IHC indicates antibody interaction with 
vascular endothelium (Figure 4). However, recognizing that complement independent path-
ways may be involved in the etiopathogenesis of AMR, the Banff classification also sets forth 
certain criteria (listed in Table 1) that allow for the diagnosis of acute or chronic AMR in 
patients without detectable C4d staining. Demonstration of circulating DSAs is a pre-requisite 
for diagnosis of AMR. Noting that non-HLA DSAs may result in clinical and histopathologic 
findings indistinguishable from AMR, Banff criteria for serologic evidence of DSAs require 
detection of either DSAs directed against donor HLA or “other” antigens [24].
C4d staining without 
evidence of rejection
All three features must be present for diagnosis:
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or 
C4d >0 by IHC on paraffin sections
2. g = 0, ptc = 0, cg = 0 (by light microscopy and by EM if available), v = 0; no TMA, no 
peritubular capillary basement membrane multilayering, no acute tubular injury (in the 
absence of another apparent cause for this)
3. No acute cell-mediated rejection (Banff 1997 type 1A or greater) or borderline changes
g-glomerulitis, ptc-peritubular capillaritis, v-vasculitis, cg-chronic glomerulopathy (transplant glomerulopathy)
Table 1. Criteria for antibody mediated rejection as outlined by the Banff 2015 Meeting Work Group [24].
Figure 2. Black arrows show infiltrating polymorphonuclear leukocytes in glomerular capillary loops (glomerulitis) in a 
patient undergoing acute oliguric antibody mediated rejection. Yellow arrows point to demarginated polymorphonuclear 
leukocytes in peritubular capillaries (peritubular capillaritis). Pathology slides courtesy: Dr. Ming Wu, Department of 
Pathology, NYU Langone Medical Center.
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Figure 3. Platelet fibrin thrombi in glomerular capillary loops (black arrow) due to acute thrombotic microangiopathy 
in a patient with acute antibody mediated rejection. Pathology slides courtesy: Dr. Ming Wu, Department of Pathology, 
NYU Langone Medical Center.
Figure 4. Immunofluorescence staining showing diffuse linear C4d positivity in peritubular capillaries (white arrows). 
Pathology slides courtesy: Dr. Ming Wu, Department of Pathology, NYU Langone Medical Center.
5. HLA antibody detection assays
5.1. Calculated panel reactive antibody (cPRA)
In the complement-dependent cytotoxicity (CDC) assay, recipient serum is mixed with 
donor lymphocytes and complement is supplemented. Presence of DSAs is indicated by the 
appearance of cytotoxicity. The CDC crossmatch was principal technique for detecting DSAs 
in kidney transplant candidates till the mid-1980s [12, 15]. The panel reactive antibody (PRA) 
assay, a simple test that predicts the likelihood of a transplant candidate finding a HLA com-
patible donor (with a negative CDC crossmatch). This test involves treating a panel of cells 
derived from a pool of individuals representative of the local donor population with recipi-
ent serum and noting the percentage of cells that develop cytotoxicity. Therefore, a patient 
with a high PRA percentage can be predicted to be HLA incompatible with a majority of the 
potential donors. Consequently, such patients have prolonged wait times for transplantation 
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and may die waiting for a compatible organ [25]. The emergence of more sensitive solid 
phase assays that employ HLA antigen-coated beads have revealed a greater prevalence 
of pre-sensitization to HLA in potential transplant recipients than was previously appreci-
ated. Using these sensitive techniques of HLA antibody detection (in recipient serum) in 
conjunction with modern HLA typing methods (to determine donor HLA typing), we can 
now estimate a transplant candidate’s calculated panel reactive antibody (cPRA). This is an 
alternative to standard PRA testing. Transplant centers can designate HLA antigens to which 
the patient has been sensitized as “unacceptable.” The cPRA is computed from HLA anti-
gen frequencies among kidney donors in the United States and represents the percentage 
of actual organ donors that express any “unacceptable” HLA antigens [25]. One of the key 
elements of the Organ Procurement and Transplantation Network’s (OPTN) new Kidney 
Allocation System (KAS) introduced in December 2014 is to allocate additional points to 
waitlisted kidney transplant candidates based on a CPRA sliding scale [26]. The aim of this 
policy is to increase access to transplantation for sensitized candidates [27]. Soon after the 
new KAS came into effect, the proportion of transplants being performed in patients with 
CPRA >98% rose from 2.4 to 13.4% [28]. Therefore, the new KAS appears to be accomplishing 
the goal of equitable allocation of scarce deceased donor organs to highly sensitized patients 
who are biologically disadvantaged.
5.2. HLA antibody detection assays
Techniques for detection of HLA antibodies in transplant candidates have evolved consid-
erably since the 1960s when the traditional cell-based complement dependent cytotoxicity 
(CDC) assay was first developed. Modern flow-cytometry and solid phase assays are far more 
sensitive than the CDC crossmatch. In the CDC crossmatch, recipient serum is incubated with 
donor lymphocytes, along with complement. A positive crossmatch is said to occur when 
DSAs present in the recipient serum bind the corresponding antigens expressed on the sur-
face of donor T or B lymphocytes and activate complement leading to cell lysis [29]. The flow 
cytometry crossmatch (FCXM) developed in the 1980s was shown to be more sensitive than 
the CDC crossmatch and can detect lower strength, but clinically significant antibodies that 
are imperceptible to the CDC crossmatch [30]. In the FCXM, like the CDC crossmatch, donor-
specific anti-HLA antibodies, if present in the recipient serum, bind HLA molecules on the 
surface of donor T or B lymphocytes. The flow cytometry technique detects these HLA bound 
anti-HLA antibodies by means of secondary fluorescein-labelled antihuman IgG [29]. The 
advent of solid phase assays for HLA antibody screening in the 1990s has redefined what it 
means to be sensitized to HLA. There are two varieties of solid phase assays – enzyme linked 
immunosorbent assay (ELISA) based methods and single antigen bead based methods. Single 
antigen bead based assays may employ either a flow cytometry platform or a Luminex plat-
form to detect HLA [31]. The Luminex platform employs fluorochrome impregnated micro-
beads that are coated with specific HLA molecules. Donor-specific anti-HLA antibodies, if 
present in the recipient serum, bind HLA molecules coated on the surface of the beads. The 
microbeads are then incubated with phycoerythrin (PE)-labeled anti-human IgG antibodies. 
The Luminex dual laser system identifies the specificity of the bound anti-HLA antibodies[Ref]. 
The Luminex based assay has now become the most popular method of HLA antibody detec-
tion, both due to its superior sensitivity, as well as its ability to identify the antigenic specific-
ity of the detected HLA antibody [29].
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6. Treatments for antibody mediated rejection
The success of desensitization techniques, which enabled transplantation in the setting 
of pre-existing DSA, represented a breakthrough in the ability to offer transplantation 
to highly-sensitized patients, who previously had little hope of receiving a transplant 
[32–34]. But early success was tempered by observations of antibody rebound, early AMR, 
and suboptimal long-term graft survival [35, 36]. Thus the ability to successfully perform 
incompatible transplants and optimize long-term outcomes is contingent upon the abil-
ity to successfully treat AMR. The first reported efforts at allograft rescue in the setting 
AMR employed similar techniques as were used for desensitization, namely, techniques 
that remove or reduce circulating antibody [37]. While removal of antibody remains the 
cornerstone of AMR therapy, improved understanding of the pathophysiological mecha-
nisms of antibody production and antibody mediated injury have yielded several adjunc-
tive treatment options which are now in various stages of application or new development. 
For treatment of AMR, no standard protocols exist. Published reports are generally small 
patient series, and reported techniques vary based on center-specific experience and exper-
tise, as well as center-specific access to emerging therapies [38–40]. Thus, randomized-
controlled trial data do not exist for most of these treatments. Meta-analyses are limited 
by patient heterogeneity, treatment regimen heterogeneity and sample size [39, 41]. Below 
are brief descriptions of currently existing treatment modalities, though it is important 
to understand that these are rarely, if ever, used as monotherapies. Most AMR treatment 
strategies employ a technique for antibody removal in combination with adjunctive agents 
to minimize antibody production and/or act at the level of the graft to minimize antibody-
mediated injury.
6.1. Therapeutic plasma exchange
Though often referred to simply as “plasmapheresis,” the procedure utilized in the treat-
ment of AMR is more accurately described as therapeutic plasma exchange (TPE). While 
plasmapheresis [42] technically describes plasma removal without replacement, TPE 
entails plasma removal with replacement of a substitute colloid component. A 1–1.5 L 
plasma volume exchange generally removes approximately 70% of plasma components, 
including anti-HLA antibodies [43]. For immunoglobulins, the durability this treatment 
differs dependent upon the tissue compartments in which each immunoglobulin subclass 
resides. IgM, which resides solely in the intravascular space, and does not significantly 
repopulate by re-equilibration following TPE, much unlike IgG and IgA. Re-equilibration 
into the intravascular space generally means that for IgG present in high concentration 
initially in the serum, multiple TPE treatments are required to make measurable impact on 
the circulating concentration [44–46]. Rates of antibody removal with TPE, as well as char-
acteristics of rebound following treatment vary with antibody subclass and specificity, and 
mechanistically this remains poorly understood [47]. TPE was one of the first reported suc-
cessful strategies for treatment AMR and remains a cornerstone of most current treatment 
protocols [37, 38, 48, 49].
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6.2. Immunoadsorption
Immunoadsorption (IA) is a therapy not available worldwide, but where applied has been 
used successfully in both desensitization and treatment of AMR. IA has the benefit of spe-
cifically removing circulating IgG, while sparing desired plasma protein components such as 
clotting factors [50]. IA can rapidly and efficiently deplete IgG after a small number of treat-
ments [51–53]. A single randomized controlled trial reporting IA plus pulse steroid compared 
to pulse steroid alone as treatment for AMR was stopped early after an excessive number of 
graft failures in the control group [54].
6.3. Intravenous immune globulin (IVIG)
The precise mechanisms of IVIG action both in desensitization and in treatment of AMR 
remain unclear, but there is evidence to support that it is multimodal [55, 56]. IVIG has been 
shown to have inhibitory effects on B-cells [57–59], antigen presenting cells [60], and on 
complement [61, 62]. IVIG in the treatment of AMR has been reported as high-dose therapy 
(1–2 gm/kg) used without plasma exchange treatments [63–65], and more commonly, as low-
dose therapy (100 mg/kg/dose) used in combination with TPE [39, 40, 66].
6.4. Splenectomy
Removal of the spleen, the largest lymphoid organ in the body, is postulated to deplete the 
plasma cell reservoir, and thereby yield a rapid decrease in circulating HLA antibody in 
patients with severe acute rejection [67, 68]. Due to its associated morbidity, splenectomy is 
generally reserved as a rescue therapy [67, 69–71] when all other less invasive interventions 
are failing and a graft is at risk for imminent loss. Potentially less morbid alternatives to 
operative splenectomy, including angioembolization or splenic irradiation, may prove to be 
beneficial in select patient situations [72].
6.5. B-cell and plasma cell targeted medical therapies
Rituximab (Rituxan ® , Genentech) is a monoclonal antibody directed against the B-cell CD20 
antigen [73]. This recombinant antibody is constructed as a chimeric protein with human IgG1 constant regions linked to murine anti-human CD20 variable regions [74]. Binding of ritux-
imab to CD20 leads to antibody-dependent complement-mediated cytotoxicity and apopto-
sis of the bound cell. Rituximab thereby depletes the memory B-cell population and this is 
hypothesized to, in turn, reduce the plasma cell population and decrease HLA-antibody pro-
duction [75–77]. Rituximab has been used as an adjunctive therapy in combination with vari-
ous treatment modalities including: IVIG [78], TPE plus steroid pulse [79, 80], and TPE plus 
IVIG [66, 81]. While rituximab was perhaps the earliest used adjunctive agent in the treatment 
of AMR, to date only a single randomized controlled trial of its use has been performed, in 
which it was compared to placebo in addition to standard therapy (TPE with low dose IVIG). 
No difference was observed in this underpowered study though there was a trend toward 
improved outcomes with the addition of rituximab [82].
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Whereas the postulated effect of rituximab on antibody-production is indirect, bortezomib 
(Velcade ® , Takeda Oncology) acts directly at the level of the antibody-producing plasma 
cell. Bortezomib is a proteasomal inhibitor that depletes circulating plasma cells by inducing 
apoptosis [83–85]. The first reported use bortezomib in transplant recipients was in a small 
series where graft salvage was attempted in the cases of AMR refractory to therapies includ-
ing TPE, IVIG, and rituximab [86]. Following bortezomib therapy, circulating DSA strength 
has been reported to decrease substantially [87], though interestingly, class I and class II DSAs 
may be not be reduced with equal efficacy [88]. Bortezomib, like rituximab, has been used in 
combination with TPE, with and without steroids and rituximab [89–92] and is thoroughly 
reviewed elsewhere [85].
6.6. Complement inhibition
The realization that the tissue injury associated with AMR was, at least in part, mediated by 
the complement cascade led to the hypothesis that complement inhibition may afford tis-
sue-level protection while TPE or other antibody removing techniques were implemented. 
The first reported use of the terminal complement inhibitor eculizumab (Soliris ® , Alexion 
Pharmaceuticals) was in a patient with severe accelerated oliguric AMR who was deemed 
an inappropriate candidate for a rescue splenectomy [93]. With TPE, IVIG, rituximab, and 
eculizumab, recovery of renal function was achieved. Several reports describe the use of 
eculizumab as a salvage therapy, either in lieu of or in combination with splenectomy 
[94–96], but reports of successful salvage are not universal [97]. Eculizumab’s mechanism 
of action of action led to studies of its pre-emptive use in incompatible kidney recipients at 
high risk for AMR, and while eculizumab may decrease the incidence of AMR [98], it does 
not prevent it [99].
Additional complement inhibitors have since become available and are being evaluated for 
their relative efficacy in AMR. C1-esterase inhibitor (C1-INH) is an endogenous protein that is 
a more proximal inhibitor of the complement cascade and is commercially available as a puri-
fied plasma preparation (Berinert ® , CSL Behring, and Cinryze ® , Shire). A recently reported 
double-blinded randomized controlled trial of C1-INH as an add-on to standard TPE therapy 
for AMR suggested a benefit in terms of improved long term renal allograft function in those 
who received C1-INH [100]. Like eculizumab, C1-INH may have promise in the prevention of 
AMR in high-risk patients [101], or as a graft protective agent in the setting of severe or treat-
ment refractory AMR [102].
6.7. IL-6 inhibition
IL-6 is a pro-inflammatory cytokine with properties that activate numerous cell lines includ-
ing B-T- and plasma cells. Tocilizumab (Actemra ® , Genentech)is a humanized monoclonal 
antibody which blocks IL-6 signal transduction by binding and inhibiting the IL-6 receptor 
[103]. In animal models, IL-6/IL-6R signaling has been found to promote renal injury [104] 
and may be associated with the injury of acute rejection [105]. In human studies, it may 
affect a decrease in HLA antibody production [106]. A recent trial of tocilizumab in patients 
with refractory chronic AMR reported improved long-term graft survival rates in those who 
received tocilizumab [107].
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7. Outcomes and unanswered questions
Generally reported estimates of the incidence of AMR are around 7% for all recipients [108], 
and may be as high as 50% among recipients of HLA-incompatible grafts [109, 110]. Despite 
improved abilities to diagnose and treat AMR, it remains an important cause of premature 
graft loss [111, 112]. Clinically silent AMR identified on biopsy in the setting of normal renal 
function, if left untreated, is associated with a two-fold increased risk of graft loss [109, 113]. If 
the AMR is clinically apparent and associated with graft dysfunction, the risk of graft loss can 
increase to six-fold [109]. Even when recognized and treated promptly, AMR portends recur-
rent AMR, and ultimately, chronic AMR and transplant glomerulopathy [114, 115].
The pathophysiology of AMR and the molecular mechanisms of antibody-mediated injury 
have never been better understood, however the fact that such heterogeneity is observed clini-
cally from case to case suggests that much remains yet to be clarified. The spectrum of AMR 
severity, acuity, and treatability is broad and not easily predictable even when clinical param-
eters appear relatively constant. While some lines of evidence suggest that any DSA [116, 117] 
even historical DSA not present at transplant [111], has the potential to be harmful, others have 
reported clinically silent DSA that, although detectable, has no apparent impact the incidence 
of rejection or on long-term outcomes [118]. Whether sensitization alone, not just DSA, is an 
independent risk factor for AMR, is unclear [115]. Whether this variability lies in the DSA speci-
ficity, in differential expression of the target HLA molecules on the allograft, or on other factors, 
remains to be determined. Multiple lines of evidence suggest that complement activating, C1q-
binding DSA are associated with greater risks for rejection and for worse outcomes [119–122], 
compared to non-C1q binding DSAs. The ability to identify and test for the more virulent DSAs 
may prove to be of benefit in terms of surveillance and directing treatment. There is evidence 
that class II DSA is associated with worse long-term outcomes [123–125], and poorer responses 
to treatments [126] compared to class I DSAs. What underlies this difference, remains uncer-
tain. Whether, and how, antigens vary in terms of their immunogenicity and risks for inciting 
AMR, remains to be determined. Whether any of the available therapies is optimally suited 
for different DSA patterns or specificities, or AMR phenotypes, also remains to be determined.
Perhaps the most effective means of minimizing the risks of AMR may be in maximizing 
efforts to prevent it. Experience with HLA-incompatible transplant recipients have demon-
strated, both in single-center and multi-center series, that long-term outcomes are inversely 
correlated with the starting crossmatch strength [19, 20]. Thus careful attention paid to 
donor selection, and making any effort possible to minimize incompatibility, can pay great 
dividends in the long-term post-transplant [115]. And while prevention will not always be 
feasible, the ability to more readily and accurately detect AMR will enable more rapid treat-
ments and improve the chances of their success. Just as new agents are being developed to 
remove antibody [127], and interrupt the pathways that impart antibody-mediated injury, 
so too are innovative, increasingly specific, and less invasive procedures for the diagnosis of 
AMR. The ability to identify AMR, and perhaps even characterize AMR phenotypes based 
on gene expression profiles in biopsy tissue [128, 129] should allow a clearer determination 
of AMR severity and ultimately help guide therapy. The identification of serum and/or uri-
nary biomarkers [130–133] should enable better surveillance, earlier diagnosis of AMR, and 
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prompt treatment to prevent irreversible tissue injury. Ultimately, optimizing the diagnosis 
and treatment of AMR will lead to greater graft longevity and thus, better utilization of this 
vastly limited resource.
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